News

Agence France-Presse19h
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
BMJ4d
Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
33 Anti-CNTN1, anti-NF155 and anti-NF140/NF186 antibodies belong to the infrequent subtype IgG4, which does not activate complement and binds less well to activating Fc gamma receptors, pointing to a ...
Beigene Presents Pioneering Cancer Research At ASCO 2025 Redefining Treatment Across Hematology And Solid Tumors - AET...
BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...
Agence France-Presse6d
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...
ahajournals.org2d
Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease
Figure 1. VEGF (vascular endothelial growth factor) ligands and receptors. VEGFs and PIGF (placental growth factor) can interact with a combination of various VEGFRs (VEGF receptors), which are a part ...